An updated patent review on ocular drug delivery systems with potential for commercial viability

Recent Patents on Drug Delivery and Formulation

Volumn 5, Issue 2, 2011, Pages 146-162

  Srivastava, Rishabh ^a   Pathak, Kamla ^a  

^a NH 2   (India)

Author keywords

Liquid ocular system; Miscellaneous ocular system; Ocular delivery; Semisolid ocular system; Solid ocular system

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; APOMORPHINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIMATOPROST; CORTICOSTEROID; CYCLODEXTRIN; CYCLOSPORIN A; DEXAMETHASONE; DORZOLAMIDE; FLUORESCEIN; GATIFLOXACIN; GLUCOCORTICOID; HYDROXYPROPYLMETHYLCELLULOSE; LATANOPROST; LIDOCAINE; MACROGOL; MEMANTINE; MOLECULAR SCAFFOLD; NAPHAZOLINE; NEPAFENAC; NEUROTRANSMITTER; PILOCARPINE; POLYGLACTIN; POLYMER; PROSTAGLANDIN; RAPAMYCIN; REBAMIPIDE; TIMOLOL MALEATE; TYLOXAPOL; UNINDEXED DRUG;

AEROSOL; BACTERIAL INFECTION; BIODEGRADABLE IMPLANT; BLOOD BRAIN BARRIER; CATARACT; COLLOID; CONJUNCTIVITIS; CONTACT LENS; CORNEA PERMEABILITY; DOSE CALCULATION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG IMPLANTATION; DRUG MARKETING; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TARGETING; DRY EYE; EYE DISEASE; GLAUCOMA; HUMAN; HYDROGEL; INTRAOCULAR HYPERTENSION; IONTOPHORESIS; KERATITIS; LIPOPHILICITY; NONHUMAN; OPEN ANGLE GLAUCOMA; PARKINSON DISEASE; PRESBYOPIA; PRIORITY JOURNAL; REVIEW; SUSTAINED RELEASE FORMULATION; UVEITIS; VISUAL DISORDER;

DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; EYE DISEASES; HUMANS; OPHTHALMIC SOLUTIONS; PATENTS AS TOPIC;

EID: 79955654103     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221111795471436     Document Type: Review

References (86)

1. Sultana Y, Jain R, Rathod R, Ali A, Aqil, M. Advances inophthalmic drug delivery systems: Part I. Latest Rev 2005; 3(2). Available at http://www.pharmainfo.net/reviews/advancesophthalmic-drug-delivery-systems-part-i. Accessed on Dec 05,2010
2. Kumar GJ, Sudharshan H, Chanukya RD, Mitra AK. RecentPatents and advances in ophthalmic drug delivery. Recent Pat DrugDeliv Formul 2007; 1(2): 161-70.
3. Lang JC, Roehrs RE, Rodeheaver DP, Missel PJ, Jani R, ChowhanMA. Design and evaluation of ophthalmic pharmaceuticalproducts. In Banker GS, Rhodes CT, Eds. Modern Pharmaceutics. 4 ed. New York, Marcel Dekker 2002; 415-78.
4. Conway BR. Recent patents on ocular drug delivery systems. Recent Pat Drug Deliv Formul 2008; 2(1): 1-8.
5. Conway, B.R., Gherghel, D. Chronotherapeutic ocular deliverysystem comprising a combination of a prostaglandin and a betablocker for treating primary glaucoma. US20090155338 (2009).
6. Oldrich, S.A., Glazer, L.C. Drug delivery via ocular implant. US20100040670 (2010).
7. Robinson, M.R., Burke, J.A., Liu, H., Orilla, W., Spada, L.T., Ghebremeskel, A.N., Hughes, P.M., Xu, K., Do, M.M. Intraocularsustained release drug delivery systems and methods for treatingocular conditions. WO2010111449 (2010).
8. Philips, B., Bague, S., Rabinovich-Guilatt, L., Lambert, G.Ophthalmic emulsions containing prostaglandins. Applicationnumber 1290/KOLNP/2008 (2008). available at http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=1290/KOLNP/2008 (Accessed onNov. 30, 2010).
9. Carli, F., Baronian, M., Schmid, R., Chiellini, E. Ophthalmic oil-inwateremulsions containing prostaglandins. Application number3566/KOLNP/2009 (2009) available at http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=3566/KOLNP/2009 (Accessed onDec. 03, 2010).
10. Mitra, A.K., Velagaleti, P.R., Grau, U.M. Topical drug deliverysystems for ophthalmic use. WO2010144194 (2010).
11. Hughes, P.M. Hypotensive lipid-containing biodegradableintraocular implants and related methods. Application number5093/DELNP/2006 (2007). available at http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=5093/DELNP/2006 (Accessed onNov. 28, 2010).
12. Raiche, A.T., Salamone, J.C. Method for the production ofnanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility. WO2006137856(2006).
13. Faour, J., Pastini, A.C. Ophthalmic solutions. EP2070518 (2009).
14. Paul, A, Haug, G. Sustained release device and method for oculardelivery of adrenergic agents. Application number 2182/DELNP/2009 (2009). available at http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=2182/DELNP/2009 (Accessed on Nov. 28, 2010).
15. Schultz, C.L., Mint, J.M. Drug delivery system forantiglaucomatous medication. US6410045 (2002).
16. Isowaki, A. Percutanously absorbable ophthalmic preparation.EP1917964 (2008).
17. Ambati, B.K., Gale, B.K. Intraocular drug delivery device andassociated methods. WO2009140246 (2009).
18. Mainde, C., Achliya, G.S., Bora, S.P. Gel forming ophthalmicsolutions of naphazoline or salt therof. Application number614/MUM/2007 (2007). available at http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=614/MUM/2007 (Accessed on Dec. 05, 2010).
19. Mainde, C., Achliya, G.S., Bora, S.P. Gel forming ophthalmicsolutions. Application number 615/MUM/2007 (2007). available at http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=615/MUM/2007 (Accessed onDec. 05, 2010).
20. Mainde, C., Achliya, G.S., Bora, S.P. Gel forming ophthalmicsolutions of dorzolamide or salt therof. Application Number616/MUM/2007 (2007). available at http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=616/MUM/2007 (Accessed on Dec. 06, 2010).
21. Sawa. Aqueous liquid preparation having improved intraoculargatifloxacin penetration. Application number 1982/CHENP/2009(2009). available at http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_Number=1982/CHENP/2009&AspxAutoDetectCookieSupport=1 (Accessed on Dec.01, 2010).
22. Higuchi, J.W. Noninvasive ocular delivery of rapamycin.US20100040669 (2010).
23. Warren, S.L., Osborne, D.W., Holl, R. Adhesive bioerodible oculardrug delivery system. US20050013845 (2005).
24. Libin, B., Liebmann, J.M., Chen, W. Hypercompressed particlesfor controlled release of ophthalmic medications. WO200814390(2008).
25. Libin, B., Liebmann, J.M., Chen, W. Controlled release dispensingdevice. WO2010123563 (2010).
26. Leahy, C.D., Labombard, D. Ocular drug delivery device. US20070112318 (2007).
27. Brubaker, M.J., Krishnamoorthy, R., Lesczynski, M.A., Natalie, T.F., Papadopoulos, P., Renner, S.B., Viscasillus, S., Martin, A.E., Shropshire, J.P. Sustained release drug delivery devices. US6756049 (2004).
28. Yaacobi, Y. Ophthalmic drug delivery device. US20040106906,US20040131655 (2004), US6986900 (2006) and US7094226(2006).
29. Loftsson, T., Stefansson, E. Cyclodextrin nanotechnology forophthalmic drug delivery. WO2007012974 (2007).
30. Leahy, C., Ellis, E., Ellis, J.Y. Ophthalmic drug delivery systemand application. US20100233241 (2010).
31. Pipkin, J.D., Zimmerer, R.O., Siebert, J.M. Nasal and ophthalmicdelivery of aqueous corticosteroid solutions. WO2009003199(2009).
32. Byrne, M.E., Venkatesm, S. Contact drug delivery system.WO2006084275 (2006).
33. Patrizia, C., Susi, B., Daniela, M., Fabrizio, S.M. Ophthalmiccompositions containing mucoadhesive polysaccharides able topromote corneal re-epthelization. Application Number1123/DELNP/2008 (2008). available at http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=1123/DELNP/2008 (Accessed on Nov. 30, 2010).
34. Joshi, A.V. Iontophoretic drug delivery systems. US7349733(2008).
35. Chou, D., Peng, L., Nivaggioli, T. Biodegradable ocular implant. EO1917957 (2008).
36. Chauhan, A., Kapoor, Y. Contact lens based bioactive agentdelivery system. WO2009032267 (2009).
37. Philips, B., Bague, S., Rabinovich-Guilatt, L., Lambert, G.Ophthalmic emulsions containing immunosuppressive agent. Application Number 1664/KOLNP/2007 (2007). available at http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=1664/KOLNP/2007 (Accessed onNov. 30, 2010).
38. Yu-Zhi, J. Omega-3 oil containing ophthalmic emulsions.WO2010141591 (2010).
39. Li, X., Jasti, B.R., Mahalingam, R. Ocular agent delivery systems. WO2006039558 (2006).
40. Kunjler, J.F., Jani, D.M. Drug delivery devices. US20080145405(2008).
41. Chauhan, A., Gulsen, D. A system for the delivery of ophthalmicdrugs. Application Number 3841/DELNP/2004 (2009). available at http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=3841/DELNP/2004 (Accessed onNov. 29, 2010).
42. Burkzinsky, F., Cotem D. Ocular inserts containing apomorphine. US20080171072 (2008).
43. Ells, S.E. Drug eluting ocular conformer. US20090162417 (2009).
44. Schacher, R.A. An ocular scleral prosthesis. Application number1544/DEL/1998 (2006). available at http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=1544/DEL/1998 (Accessed on Nov. 28, 2010).
45. Lehman, C. Hydrogel intraocular lens and method of formingsame. Application number 3224/KOLNP/2010 (2010). available at http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=3224/KOLNP/2010 (Accessed onNov. 29, 2010).
46. Lyons, R.T., Burke, J.A., Robinson, M.R. Biodegradable drugdelivery system. US20080292679 (2008).
47. Greenberg, R. Implantable drug delivery device. US7527621(2009).
48. Ding, S. Recent developments in ophthalmic drug delivery. PharmSci Tech Today 1998; 1(8): 328-35. doi:10.1016/S1461-5347(98)00087-X.
49. Warren, S.L., Osborne, D.W., Holl, R. Adhesive bioerodible oculardrug delivery system. US20080268021 (2008).
50. Sibambo, S.R., Pillay, V., Choonara, Y.E. Monolithic drug deliverysystem. US20100068169 (2010).
51. Williams, S.F. Flushable disposable polymeric products.WO2001015671 (2001).
52. Darougar, S., Darougar, D. Ocular insert. US6264971 (2001).
53. Unger, E.C. Acoustically active drug delivery systems. US6416740(2002).
54. Wong, V.G., Hu, M.W.L., Berger, D.E. Controlled releasebiocompatible ocular drug delivery implant devices and methods. US6331313 (2001).
55. Ishikawa, A., Takeda, N., Ahn, S.I., Ahn, S.S., Hayes, S.R., Gaffney, A.F. Implantable drug delivery systems. US6464687(2002).
56. Yaacobi, Y. Ophthalmic drug delivery device. US6416777 (2002).
57. Snyder, M.E., Dobrusin, E.M. Sustained release ophthalmologicaldevice and method of making and using the same. WO2003061625(2003).
58. Chauhan, A., Gulsen, D. Ophthalmic drug delivery device. US20040096477 & US20040241207 (2004).
59. Mudumba, S., Dor, P.J.M., Nivaggioli, T., Weber, D.A., Farooq, S. Drug delivery systems for treatment of diseases or conditions. WO2006102378 (2006).
60. Thierry, N., Lin, P., David, C., David, W. Biodegradable ocularimplant. Application Number 01107/KOLNP/2005 (2007).available at http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=01107/KOLNP/2005 (Accessed onNov. 28, 2010).
61. May, G., Carlsson, D.J., Li, F. An ocular implant. Applicationnumber 1209/CHENP/2007 (2007). available at http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=1209/CHENP/2007 (Accessed onNov. 28, 2010).
62. Bodmer D, Ahlheim M, Ausborn M, Schoch C. Ophthalmic depotformulations for periocular or subconjunctival administration. Application Number 2032/CHENP/2007 (2007). available at http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=2032/CHENP/2007 (Accessed onNov. 28, 2010).
63. Trogden, J.T., Lyons, R.T., Chang, J.N., Robinson, M.R. Ocularimplant delivery assemblies with distal caps. US20080033351(2008).
64. Trogden, J.T., Lyons, R.T., Chang, J.N., Robinson, M.R. Ocularimplant delivery assembly. US20080097335. (2008).
65. Ben, N.J. Intraocular drug dispenser. Application number5545/DELNP/2008 (2008). available at http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=5545/DELNP/2008 (Accessed on Nov. 29, 2010).
66. Frion, D., McCarville, R., Schieber, A.T., Zenz-Olson, N., Feehan, D., Matthees, E., Euteneuer, C.L. Ocular implant deliverysystemand method. US20090132040 (2009).
67. Silvestrini, T., Juan, Jr E.D., Rosenman, D. Ocular implant withhydrogel expansion capabilities. WO2009012401 (2009).
68. Erickson, S.R., Zhou, J., Punja, K., Beeley, N.R.F. Implantableocular drug delivery device and methods. US20100189765 (2010).
69. Silvestrini, T.A., Lilly, R.S. Ocular implant delivery systems andmethods. US20100280317 (2010).
70. Winterton, L.C., Lally, J.M. Ophthalmic devices for sustaineddelivery of active compounds. WO2006117228 (2006).
71. Chauhan, A. Contact lens based bioactive agent delivery system. US20090060981 (2009).
72. Aviv, H.R., Friedman, D.C.Y., Bar-Ilan, A.N.M., Vered, M.R. Submicron emulsions as ocular drug delivery vehicles. EP0656779(2000).
73. Sullivan, T.R., Nelson, J. Multiple Unit dose drug delivery system. WO2005102058 (2005).
74. Matsuda, T., Hiraoka, S., Tomohira, Y., Ishikawa, S. Aqueousophthalmic suspension of crystalline rebamipide. Applicationnumber 4061/DELNP/2007 (2007). available at http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=4061/DELNP/2007 (Accessed onNov. 30, 2010).
75. Mazzone, M.G., Moschetti, V.M.C., Miano, F.G., Lo Grasso, L.G. Pharmaceutical formulations based on apolar and polar lipids forophthalmic use. Application number 5767/CHENP/2009 (2009).Available at http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=5767/CHENP/2009(Accessed on Dec. 01, 2010).
76. Rice, M.W. Ocular drug delivery nebulizer. WO2002072169(2002).
77. James, F.C., Chinnock, R.B., Melonson, J., Howard, J. Ophthalmicdrug delivery system. Application number 5339/DELNP/2005(2007). available at http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=5339/DELNP/2005 (Accessed on Dec. 03, 2010).
78. Ravi, N., Ali, A.H. Hydrogel nanocomposites for ophthalmicapplications. Application Number 1135/DELNP/2006 (2007).available at http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=1135/DELNP/2006 (Accessed on Dec. 03, 2010).
79. Xia, E., Smerbeck, R.V. Reversible gelling system for ocular drugdelivery. Application number 00873/DELNP/2003 (2007).avaialable at http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=00873/DELNP//2003 (Accessed on Dec. 05, 2010).
80. Longo, A., Santaniello, M., Pescosolido, N., Koverech, A. Geluseful for the delivery of ophthalmic drugs. WO2008077712(2008).
81. Chauhan, A., Li, C., Jung, H. Dispersions of microparticles andmicrogels in hydrogels for drug delivery. WO2009032266 (2009).
82. Haug, C., Jonat, S. In situ gelling systems as sustained delivery forfront of eye. WO2009150209 (2009).
83. Miller, D.J., Li, S.K., Higuhi, W. Non-invasive ocular drugdelivery. US20040071761 (2004).
84. Roy, P. Ocular iontophoresis device. Application number2306/KOLNP/2008 (2009). available at http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=2306/KOLNP/2008 (Accessed on Dec. 06, 2010).
85. Tomich, J.M., Iwamoto, T. Peptide enhanced corneal drug delivery. US11304929 (2005).
86. Abdulrazik, M. Method of central nervous targeting through theocular route of drug delivery. US20030181354 (2003).